SG11201907814SA - Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof - Google Patents
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereofInfo
- Publication number
- SG11201907814SA SG11201907814SA SG11201907814SA SG11201907814SA SG11201907814SA SG 11201907814S A SG11201907814S A SG 11201907814SA SG 11201907814S A SG11201907814S A SG 11201907814SA SG 11201907814S A SG11201907814S A SG 11201907814SA SG 11201907814S A SG11201907814S A SG 11201907814SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- international
- pct
- september
- march
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 230000001105 regulatory effect Effects 0.000 title abstract 4
- 210000004698 lymphocyte Anatomy 0.000 title abstract 3
- 230000002463 transducing effect Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001589 lymphoproliferative effect Effects 0.000 abstract 1
- 230000000051 modifying effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIP0 I PCT onion °nolo mu oloiloilooimmo oimIE (10) International Publication Number WO 2018/161064 Al (71) Applicant: Fl ONCOLOGY, INC. [US/US]; 625 N. Fla- gler Dr., Suite 625, West Palm Beach, Florida 33401 (US). (72) Inventors: FROST, Gregory Ian; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). ONUFFER, James Joseph; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). GUIBINGA, Ghiabe H.; 1613 Fort Stockton Drive, San Diego, California 92103 (US). HAERIZADEH, Farzad; 13954 Royal Dornoch Square, SAN DIEGO, California 92128 (US). (74) Agent: VACCHIANO, Emanuel J.; 8110 Woodside Lane, Burr Ridge, Illinois 60527 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (51) International Patent Classification: C12N 15/10 (2006.01) CO7K 14/705 (2006.01) C12N 15/867 (2006.01) CO7K 14/715 (2006.01) C12N 5/0783 (2010.01) A61K 48/00 (2006.01) C12N 5/10 (2006.01) C12N 15/86 (2006.01) CO7K 14/725 (2006.01) (21) International Application Number: PCT/US2018/020818 (22) International Filing Date: 03 March 2018 (03.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/467,039 03 March 2017 (03.03.2017) US 15/462,855 19 March 2017 (19.03.2017) US PCT/US2017/023112 19 March 2017 (19.03.2017) US 15/644,778 08 July 2017 (08.07.2017) US PCT/US2017/041277 08 July 2017 (08.07.2017) US 62/560,176 18 September 2017 (18.09.2017) US 62/564,253 27 September 2017 (27.09.2017) US 62/564,991 28 September 2017 (28.09.2017) US — (54) Title: METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING = THE ACTIVITY THEREOF W O 20 18/ 16 106 4 Al (57) : The present disclosure provides methods for genetically modify- ing lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphopro- liferative element, and/or a chimeric antigen receptor (CAR), for example a microen- vironment restricted biologic CAR (MRB-CAR). Additional elements of such engi- neered signaling polypeptides are provided herein, such as those that drive prolifer- ation and regulatory elements therefor, as well as replication incompetent recombi- nant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically mod- ified T cells and/or NK cells are provided, such as, for example, those including ri- boswitches, MRB-CARs, recognition domains, and/or pH-modulating agents. [Continued on next page] WO 2018/161064 Al MIDEDIM01101 DIV IIMOU1111111111111111111111111111101111111110111111111111 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762467039P | 2017-03-03 | 2017-03-03 | |
US15/462,855 US10596274B2 (en) | 2016-03-19 | 2017-03-19 | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
PCT/US2017/023112 WO2017165245A2 (en) | 2016-03-19 | 2017-03-19 | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
US15/644,778 US11111505B2 (en) | 2016-03-19 | 2017-07-08 | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
PCT/US2017/041277 WO2018009923A1 (en) | 2016-07-08 | 2017-07-08 | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
US201762560176P | 2017-09-18 | 2017-09-18 | |
US201762564253P | 2017-09-27 | 2017-09-27 | |
US201762564991P | 2017-09-28 | 2017-09-28 | |
PCT/US2018/020818 WO2018161064A1 (en) | 2017-03-03 | 2018-03-03 | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907814SA true SG11201907814SA (en) | 2019-09-27 |
Family
ID=63371106
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907814SA SG11201907814SA (en) | 2017-03-03 | 2018-03-03 | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
SG10202109571P SG10202109571PA (en) | 2017-03-03 | 2018-03-03 | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202109571P SG10202109571PA (en) | 2017-03-03 | 2018-03-03 | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3589733A1 (en) |
KR (1) | KR20200003370A (en) |
CN (1) | CN110892070A (en) |
AU (1) | AU2018226884A1 (en) |
BR (1) | BR112019018288A2 (en) |
CA (1) | CA3054064A1 (en) |
CU (1) | CU24645B1 (en) |
IL (1) | IL268739A (en) |
MX (1) | MX2019010445A (en) |
SG (2) | SG11201907814SA (en) |
TW (1) | TW201839127A (en) |
WO (1) | WO2018161064A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
EP3781177A4 (en) * | 2018-04-19 | 2022-03-02 | Baylor College of Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
WO2020160419A1 (en) * | 2019-02-01 | 2020-08-06 | The Trustees Of Dartmouth College | Signaling platforms for chimeric antigen receptor t cells |
US20220096549A1 (en) * | 2019-02-08 | 2022-03-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric cytokine receptors |
EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
EP3715368A1 (en) * | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
CN110244612B (en) * | 2019-06-06 | 2020-05-26 | 西安交通大学 | Binary digital communication system based on chemical diffusion mechanism |
CN112500492B (en) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and application thereof |
CN114616239B (en) * | 2019-10-17 | 2023-08-11 | 北京门罗生物科技有限公司 | Chimeric antigen receptor and T cell expressing chimeric antigen receptor therein |
WO2021108677A1 (en) * | 2019-11-27 | 2021-06-03 | Board Of Regents, The University Of Texas System | Natural killer cell immunotherapy for the treatment of glioblastoma and other cancers |
US20230111159A1 (en) * | 2020-03-05 | 2023-04-13 | Exuma Biotech Corp | Methods and compositions for the delivery of modified lymphocyte aggregates |
CN111662900B (en) * | 2020-05-13 | 2023-06-27 | 重庆师范大学 | Sulfadimidine aptamer screening method, kit and application |
CN111549044B (en) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | Preparation method and application of targeted TRBC1 CAR-T cell |
CA3204357A1 (en) * | 2021-01-28 | 2022-08-04 | Todd LUMAN | Methods for transducing immune cells |
WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
CN117683139A (en) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | Constitutive chimeric cytokine receptor, immune cell expressing same and application thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
ES2249761T3 (en) | 1993-06-24 | 2006-04-01 | Advec Inc. | ADENOVIRUS VECTORS FOR GENE THERAPY. |
EP2113569A1 (en) | 1993-10-25 | 2009-11-04 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
PT889120E (en) | 1994-12-09 | 2002-09-30 | Microscience Ltd | VIRULENCE GENES IN SALMONELLA VGC2 GROUP |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
KR20000076157A (en) | 1997-03-11 | 2000-12-26 | 리전츠 오브 더 유니버스티 오브 미네소타 | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6916846B2 (en) | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
US7387896B2 (en) | 2003-03-26 | 2008-06-17 | The Regents Of The University Of Michigan | MicroRNA vectors |
CN1897977A (en) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | In vivo gene therapy of parkinson's disease |
WO2006007539A1 (en) * | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
KR20070111448A (en) | 2004-11-08 | 2007-11-21 | 예일 유니버시티 | Riboswitches, structure-based compound design with riboswitches, and methods and compositions for use of and with riboswitches |
US8236925B1 (en) | 2005-08-26 | 2012-08-07 | University Of Minnesota | Protein nanorings |
US20100260739A1 (en) | 2009-03-09 | 2010-10-14 | Bioatla, Llc | Mirac Proteins |
ES2717629T3 (en) | 2009-11-03 | 2019-06-24 | Hope City | Truncated epidermal growth factor receptor (EGFRt) for selection of transduced T cells |
CN103582699B (en) * | 2011-04-08 | 2017-03-22 | 贝勒医学院 | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
DK2997134T3 (en) * | 2013-05-14 | 2020-09-28 | Univ Texas | HUMAN USE OF GENANIZED CHIMARY ANTIGEN RECEPTOR (CAR) T CELLS |
JP7286267B2 (en) | 2014-08-28 | 2023-06-05 | バイオアトラ インコーポレイテッド | Conditionally active chimeric antigen receptor for modified T cells |
GB201503500D0 (en) * | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
MX2018011345A (en) * | 2016-03-19 | 2019-05-27 | F1 Oncology Inc | Methods and compositions for transducing lymphocytes and regulated expansion thereof. |
AU2017292936C1 (en) * | 2016-07-08 | 2024-05-02 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
GB201614093D0 (en) * | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
-
2018
- 2018-03-03 SG SG11201907814SA patent/SG11201907814SA/en unknown
- 2018-03-03 CN CN201880029224.1A patent/CN110892070A/en active Pending
- 2018-03-03 SG SG10202109571P patent/SG10202109571PA/en unknown
- 2018-03-03 CA CA3054064A patent/CA3054064A1/en active Pending
- 2018-03-03 EP EP18711459.0A patent/EP3589733A1/en active Pending
- 2018-03-03 AU AU2018226884A patent/AU2018226884A1/en active Pending
- 2018-03-03 KR KR1020197029141A patent/KR20200003370A/en not_active Application Discontinuation
- 2018-03-03 CU CU2019000075A patent/CU24645B1/en unknown
- 2018-03-03 MX MX2019010445A patent/MX2019010445A/en unknown
- 2018-03-03 WO PCT/US2018/020818 patent/WO2018161064A1/en active Application Filing
- 2018-03-03 BR BR112019018288-8A patent/BR112019018288A2/en unknown
- 2018-03-05 TW TW107107278A patent/TW201839127A/en unknown
-
2019
- 2019-08-15 IL IL26873919A patent/IL268739A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200003370A (en) | 2020-01-09 |
CU20190075A7 (en) | 2020-04-02 |
AU2018226884A1 (en) | 2019-10-10 |
CA3054064A1 (en) | 2018-09-07 |
SG10202109571PA (en) | 2021-10-28 |
IL268739A (en) | 2019-10-31 |
CU24645B1 (en) | 2023-02-13 |
MX2019010445A (en) | 2019-10-24 |
WO2018161064A1 (en) | 2018-09-07 |
TW201839127A (en) | 2018-11-01 |
EP3589733A1 (en) | 2020-01-08 |
BR112019018288A2 (en) | 2020-03-31 |
WO2018161064A9 (en) | 2019-07-18 |
CN110892070A (en) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907814SA (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
SG11201805186VA (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201908658TA (en) | Nucleobase editors comprising nucleic acid programmable dna binding proteins | |
SG11201810132WA (en) | Ferroelectric memory cell recovery | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11201811405QA (en) | Improved differentiation method | |
SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
SG11201808797XA (en) | T cell receptors | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201907653QA (en) | Compositions and methods for enhanced gene expression | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201907319QA (en) | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same | |
SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof |